AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has failed to improve overall survival (OS) in ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Datopotamab deruxtecan, developed under a collaboration between AstraZeneca and Daiichi Sankyo, elicited higher overall ...

Among the first presentations at the European Society for Medical Oncology (ESMO) meeting that kicked off today, were results ...

The partners’ ADC didn’t significantly extend survival in lung cancer patients who were expected to benefit the most from ...

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...

Daiichi Sankyo Co. shares drop as much as 10.4% on Tuesday, the most since Aug. 5, after its lung cancer drug with ...

AstraZeneca's Dato-DXd faces challenges in overall survival data but holds potential for approval with promising PFS benefits ...

WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) has shown a trend toward improving overall survival (OS) compared with chemotherapy in a Phase ...

AstraZeneca (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) datopotamab deruxtecan (Dato-DXd) did not significantly improve overall ...

The Japanese cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this ...